Utilizing ISO Standards and Application of Lean Approach to 21 CFR 820

Introduction

To enhance the regulatory landscape governing medical devices, the FDA has introduced a final rule amending the Quality System Regulation, known as 21 CFR 820. This amendment aims to synchronize 21 CFR 820, which delineates current Good Manufacturing Practice (cGMP) requirements, with the internationally recognized ISO 13485:2016 standard.

This final rule includes an alignment with ISO 13485:2016. The goal is to harmonize 21 CFR 820 with ISO 13485:2016, thereby replacing part of the Quality System Regulation with the provisions outlined in the ISO standard. Additionally, Clause 3 of ISO 9000:2015, focusing on Quality Management System (QMS) fundamentals and vocabulary, will be integrated into the amended regulation. This clause contains definitions applicable to ISO 13485. The Rule will introduce definitions and requirements not explicitly stated in ISO 13485 or Clause 3 of ISO 9000, ensuring clarity and specificity within the regulatory framework.

The amended regulation will be rebranded as the “Quality Management System Regulation” (QMSR), reflecting its alignment with international standards. In addition, conforming edits will also be made for 21 CFR Part 4, addressing combination products to ensure consistency.

The QMSR rule is scheduled to take effect on February 2, 2026, aligning the United States with other nations that have adopted ISO 13485 as the foundation for cGMP medical device requirements. The overarching goal of the Final Rule is to promote global harmonization and bring FDA regulations closer to international standards, facilitating easier market access for medical devices across borders.

Importantly, ISO 13485 emphasizes risk management practices throughout the product lifecycle, a departure from the previous emphasis on design controls under the QS regulation. While ISO 13485 sets the groundwork, the QMSR rule includes provisions addressing areas not fully covered by ISO 13485 or ISO 9000, such as certain types of records and FDA-specific cGMP requirements for medical devices. Overall, the update to 21 CFR 820 represents a significant step towards modernizing and aligning the regulatory framework governing medical devices, with a focus on promoting quality, safety, and international harmonization.

Did you know?

MEDVACON’s Medical Device Quality and Compliance experts help clients by applying a risk-based methodology.  Our experienced team maximizes time and cost efficiencies through focused qualification. MEDVACON’s ability to apply industry trends and analyses to help define and implement best practices ensures rapid adaption to client project requirements. Click the button below to learn more.